Cargando…

Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer

Identifying pathogenic missense variants in hereditary cancer is critical to the efforts of patient surveillance and risk-reduction strategies. For this purpose, many different gene panels consisting of different number and/or set of genes are available and we are particularly interested in a panel...

Descripción completa

Detalles Bibliográficos
Autores principales: Keskin Karakoyun, Hilal, Yüksel, Şirin K., Amanoglu, Ilayda, Naserikhojasteh, Lara, Yeşilyurt, Ahmet, Yakıcıer, Cengiz, Timuçin, Emel, Akyerli, Cemaliye B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988940/
https://www.ncbi.nlm.nih.gov/pubmed/36896237
http://dx.doi.org/10.3389/fgene.2023.1052383
_version_ 1784901676849692672
author Keskin Karakoyun, Hilal
Yüksel, Şirin K.
Amanoglu, Ilayda
Naserikhojasteh, Lara
Yeşilyurt, Ahmet
Yakıcıer, Cengiz
Timuçin, Emel
Akyerli, Cemaliye B.
author_facet Keskin Karakoyun, Hilal
Yüksel, Şirin K.
Amanoglu, Ilayda
Naserikhojasteh, Lara
Yeşilyurt, Ahmet
Yakıcıer, Cengiz
Timuçin, Emel
Akyerli, Cemaliye B.
author_sort Keskin Karakoyun, Hilal
collection PubMed
description Identifying pathogenic missense variants in hereditary cancer is critical to the efforts of patient surveillance and risk-reduction strategies. For this purpose, many different gene panels consisting of different number and/or set of genes are available and we are particularly interested in a panel of 26 genes with a varying degree of hereditary cancer risk consisting of ABRAXAS1, ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, and XRCC2. In this study, we have compiled a collection of the missense variations reported in any of these 26 genes. More than a thousand missense variants were collected from ClinVar and the targeted screen of a breast cancer cohort of 355 patients which contributed to this set with 160 novel missense variations. We analyzed the impact of the missense variations on protein stability by five different predictors including both sequence- (SAAF2EC and MUpro) and structure-based (Maestro, mCSM, CUPSAT) predictors. For the structure-based tools, we have utilized the AlphaFold (AF2) protein structures which comprise the first structural analysis of this hereditary cancer proteins. Our results agreed with the recent benchmarks that computed the power of stability predictors in discriminating the pathogenic variants. Overall, we reported a low-to-medium-level performance for the stability predictors in discriminating pathogenic variants, except MUpro which had an AUROC of 0.534 (95% CI [0.499–0.570]). The AUROC values ranged between 0.614–0.719 for the total set and 0.596–0.682 for the set with high AF2 confidence regions. Furthermore, our findings revealed that the confidence score for a given variant in the AF2 structure could alone predict pathogenicity more robustly than any of the tested stability predictors with an AUROC of 0.852. Altogether, this study represents the first structural analysis of the 26 hereditary cancer genes underscoring 1) the thermodynamic stability predicted from AF2 structures as a moderate and 2) the confidence score of AF2 as a strong descriptor for variant pathogenicity.
format Online
Article
Text
id pubmed-9988940
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99889402023-03-08 Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer Keskin Karakoyun, Hilal Yüksel, Şirin K. Amanoglu, Ilayda Naserikhojasteh, Lara Yeşilyurt, Ahmet Yakıcıer, Cengiz Timuçin, Emel Akyerli, Cemaliye B. Front Genet Genetics Identifying pathogenic missense variants in hereditary cancer is critical to the efforts of patient surveillance and risk-reduction strategies. For this purpose, many different gene panels consisting of different number and/or set of genes are available and we are particularly interested in a panel of 26 genes with a varying degree of hereditary cancer risk consisting of ABRAXAS1, ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, and XRCC2. In this study, we have compiled a collection of the missense variations reported in any of these 26 genes. More than a thousand missense variants were collected from ClinVar and the targeted screen of a breast cancer cohort of 355 patients which contributed to this set with 160 novel missense variations. We analyzed the impact of the missense variations on protein stability by five different predictors including both sequence- (SAAF2EC and MUpro) and structure-based (Maestro, mCSM, CUPSAT) predictors. For the structure-based tools, we have utilized the AlphaFold (AF2) protein structures which comprise the first structural analysis of this hereditary cancer proteins. Our results agreed with the recent benchmarks that computed the power of stability predictors in discriminating the pathogenic variants. Overall, we reported a low-to-medium-level performance for the stability predictors in discriminating pathogenic variants, except MUpro which had an AUROC of 0.534 (95% CI [0.499–0.570]). The AUROC values ranged between 0.614–0.719 for the total set and 0.596–0.682 for the set with high AF2 confidence regions. Furthermore, our findings revealed that the confidence score for a given variant in the AF2 structure could alone predict pathogenicity more robustly than any of the tested stability predictors with an AUROC of 0.852. Altogether, this study represents the first structural analysis of the 26 hereditary cancer genes underscoring 1) the thermodynamic stability predicted from AF2 structures as a moderate and 2) the confidence score of AF2 as a strong descriptor for variant pathogenicity. Frontiers Media S.A. 2023-02-21 /pmc/articles/PMC9988940/ /pubmed/36896237 http://dx.doi.org/10.3389/fgene.2023.1052383 Text en Copyright © 2023 Keskin Karakoyun, Yüksel, Amanoglu, Naserikhojasteh, Yeşilyurt, Yakıcıer, Timuçin and Akyerli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Keskin Karakoyun, Hilal
Yüksel, Şirin K.
Amanoglu, Ilayda
Naserikhojasteh, Lara
Yeşilyurt, Ahmet
Yakıcıer, Cengiz
Timuçin, Emel
Akyerli, Cemaliye B.
Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title_full Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title_fullStr Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title_full_unstemmed Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title_short Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
title_sort evaluation of alphafold structure-based protein stability prediction on missense variations in cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988940/
https://www.ncbi.nlm.nih.gov/pubmed/36896237
http://dx.doi.org/10.3389/fgene.2023.1052383
work_keys_str_mv AT keskinkarakoyunhilal evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT yukselsirink evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT amanogluilayda evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT naserikhojastehlara evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT yesilyurtahmet evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT yakıcıercengiz evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT timucinemel evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer
AT akyerlicemaliyeb evaluationofalphafoldstructurebasedproteinstabilitypredictiononmissensevariationsincancer